Clinical trial on the effectiveness and safety of botulinum toxin type A (incobotulinumtoxin) in doses adapted to the individual needs of patients with severe spasticity

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517668-51-01

Acronym

ESPSEVMOLIN2022

Enrollment

Registered

2024-10-02

Start date

2023-05-03

Completion date

Unknown

Last updated

2024-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

brain damage oriented spasticity

Brief summary

Asworth scale at 6 weeks of treatment

Detailed description

Pain: Variation on the VAS scale (0-10) at 6 and 12 weeks of treatment, Effect on the Asworth scale at 12 weeks from drug infiltration, Barthel scale at 6 and 12 weeks after injection, Satisfaction with treatment, Assess the safety and tolerability of the treatment

Interventions

DRUGXEOMIN 50 unidades polvo para solución inyectable

DRUGBOTULINUM TOXIN TYPE A

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Asworth scale at 6 weeks of treatment	—

Secondary

Measure	Time frame
Pain: Variation on the VAS scale (0-10) at 6 and 12 weeks of treatment, Effect on the Asworth scale at 12 weeks from drug infiltration, Barthel scale at 6 and 12 weeks after injection, Satisfaction with treatment, Assess the safety and tolerability of the treatment	—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026